Lee Schechter
Private Equity Investor bei DRI Capital, Inc.
Profil
Lee Schechter is Head of Sourcing Investments at DRI Healthcare.
Prior to DRI Healthcare he was Executive Director of Mergers and Acquisitions at Novartis where he led execution of large and mid-size mergers and acquisitions across Novartis’ business units and therapeutic areas.
Prior to that he was Director of Corporate Development at Shionogi with a focus on acquisitions, in-licensing and out-licensing transactions in infectious disease, gastrointestinal and hepatology.
Previously Mr. Schechter spent over a decade on UBS’s healthcare investment banking team where he originated and executed biopharmaceutical and healthcare services transactions.
Mr. Schechter also previously worked as a Financial Analyst for a joint venture between Weill Cornell Medical and New York Presbyterian Hospital.
Mr. Schechter started his career at AT&T in the Financial Leadership Program and holds a B.S.
in Finance from Lehigh University.
Aktive Positionen von Lee Schechter
| Unternehmen | Position | Beginn |
|---|---|---|
DRI Capital, Inc.
 DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Private Equity Investor | 01.10.2022 |
Ehemalige bekannte Positionen von Lee Schechter
| Unternehmen | Position | Ende |
|---|---|---|
Shionogi, Inc.
 Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Private Equity Investor | 01.01.2019 |
Ausbildung von Lee Schechter
| Lehigh University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
DRI Capital, Inc.
DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Finance |
Shionogi, Inc.
Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Health Technology |
